Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.
Mishra MK, Wang J, Keough MB, Fan Y, Silva C, Sloka S, Hayardeny L, Brück W, Yong VW. Mishra MK, et al. Among authors: hayardeny l. Ann Clin Transl Neurol. 2014 Jun;1(6):409-22. doi: 10.1002/acn3.67. Epub 2014 May 26. Ann Clin Transl Neurol. 2014. PMID: 25356411 Free PMC article.
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.
Brück W, Pförtner R, Pham T, Zhang J, Hayardeny L, Piryatinsky V, Hanisch UK, Regen T, van Rossum D, Brakelmann L, Hagemeier K, Kuhlmann T, Stadelmann C, John GR, Kramann N, Wegner C. Brück W, et al. Among authors: hayardeny l. Acta Neuropathol. 2012 Sep;124(3):411-24. doi: 10.1007/s00401-012-1009-1. Epub 2012 Jul 6. Acta Neuropathol. 2012. PMID: 22766690 Free PMC article.
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
Wegner C, Stadelmann C, Pförtner R, Raymond E, Feigelson S, Alon R, Timan B, Hayardeny L, Brück W. Wegner C, et al. Among authors: hayardeny l. J Neuroimmunol. 2010 Oct 8;227(1-2):133-43. doi: 10.1016/j.jneuroim.2010.07.009. Epub 2010 Aug 3. J Neuroimmunol. 2010. PMID: 20684995
Laquinimod treatment in the R6/2 mouse model.
Ellrichmann G, Blusch A, Fatoba O, Brunner J, Reick C, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R. Ellrichmann G, et al. Among authors: hayardeny l. Sci Rep. 2017 Jul 10;7(1):4947. doi: 10.1038/s41598-017-04990-1. Sci Rep. 2017. PMID: 28694434 Free PMC article.
Laquinimod enhances central nervous system barrier functions.
Lühder F, Kebir H, Odoardi F, Litke T, Sonneck M, Alvarez JI, Winchenbach J, Eckert N, Hayardeny L, Sorani E, Lodygin D, Flügel A, Prat A. Lühder F, et al. Among authors: hayardeny l. Neurobiol Dis. 2017 Jun;102:60-69. doi: 10.1016/j.nbd.2017.02.002. Epub 2017 Feb 22. Neurobiol Dis. 2017. PMID: 28235673
Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.
Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S, Papapetropoulos S, Hayardeny L, Hayden MR, Chuang KH, Pouladi MA. Garcia-Miralles M, et al. Among authors: hayardeny l. Sci Rep. 2016 Aug 16;6:31652. doi: 10.1038/srep31652. Sci Rep. 2016. PMID: 27528441 Free PMC article.
36 results